Symbiox Investme (539278)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹2.87, Symbiox Investme is down to a market cap of just ₹9 Cr against a stated book value of ₹10.94 per share. That is a P/B of 0.26 — a 74% discount. A classic Graham asset play at first glance. But my first question is always: does the business earn a return on those assets? The answer is no. Sales have collapsed by 80%, net profit is down 93.75%, and the latest quarter shows both sales and net profit at zero. ROE is -0.50%, and ROCE is just 0.82%. This is not a living, compounding business; it is a shell of one. The Piotroski F-Score of 3/9 also tells me the financial health is poor. I never buy a stock merely because it looks cheap. I buy either great businesses at fair prices or assets at a deep enough discount that I can get my money out. Here, the discount is deep, but there is no clue how value will be realized. There is no dividend yield, no promoter holding data, and no earnings to anchor the P/E. The ₹10.94 book value could be worth much less if those assets are illiquid or overvalued. In a 9 crore market cap, any buyer must be careful about governance and exit. I would not rush in. I would watch for a catalyst — a sale, a buyback, or a genuine restart of operations. Until then, this is a statistical cheap stock, not a certain asset play. In the current form, I'd rather leave it for the speculator.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer